Skip to content
About
Programs
Pipeline
Patients
Team
News
Contact
News
01
AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Hypertension
9th April 2026
02
AllRock Bio Presents Phase 1 Data for Lead Program, ROC-101, at the ERS Congress
29th September 2025
03
AllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension
16th September 2025
Top
